Article Figures & Data
Figures
- Fig. 1.
A, RT-PCR analysis for NY-ESO-1 mRNA expression. mRNA from G1 TCC (Lane 1), G2 TCC (Lanes 2–5), G3 TCC (Lanes 6–8), a human bladder cancer cell line, T24 (Lane 9), and testis (Lane 10) was analyzed for NY-ESO-1 mRNA by RT-PCR. B, H&E staining (left) and immunohistostaining for NY-ESO-1 using mAb ES121 (right) in serial sections of G1, G2, or G3 TCC.
- Fig. 2.
NY-ESO-1 antibody in patients with G3 TCC. Serially diluted sera from 5 patients with G3 TCC (•), serum from an NY-ESO-1-positive patient (○), and sera from 5 healthy volunteers (□) are shown. ELISA tests with recombinant NY-ESO-1 protein are also shown.
Tables
- Table 1
Correlation between NY-ESO-1 mRNA expression and pathological and clinical features in transitional cell carcinoma
Pathological and clinical features NY-ESO-1 positive/tumors examined All tumors 20/62 (32%) Tumor gradea G1 0/4 (0%) G2 6/26 (23%) G3 14/32 (44%) Tumor invasion Superficial 10/36b (28%) Muscle invasion 10/26 (38%) Regional lymph node metastasis Negative 16/54 (30%) Positive 4/8 (50%) Systemic metastasis Negative 16/57 (28%) Positive 4/5 (80%) -
a The difference in frequency of NY-ESO-1 mRNA expression between high-grade (G3; 14 of 32) and low-grade (G1 and G2; 6 of 30) tumors was statistically significant (P < 0.05). Statistical analysis was performed by χ2 test.
-
b In this series of 36 superficial tumors, 3 were CIS, and 2 of the 3 CIS were NY-ESO-1 positive.
-
- Table 2
NY-ESO-1 antibody response in 124 patients with transitional cell carcinomaa
Tumor grade Antibody positive/sera tested G1 0/5 (0%) G2 0/47 (0%) G3 9/72b (12.5%) -
a In this series of 124 patients with TCC, both frozen tumors and sera were available from 45 patients for NY-ESO-1 RT-PCR and antibody typing. Thirteen of 45 tumors were positive for NY-ESO-1 mRNA, and 2 of the 13 patients with NY-ESO-1-positive tumors had NY-ESO-1 antibody. No NY-ESO-1 antibody was found in the 32 patients with NY-ESO-1-negative tumors.
-
b The difference in NY-ESO-1 antibody frequency in patients with high-grade (G3; 9 of 72) and low-grade (G1 and G2; 0 of 52) tumors was statistically significant (P < 0.05). Statistical analyses were performed by χ2 test.
-
- Table 3
TNM classification of TCC in patients with NY-ESO-1 antibody
Patient Primary tumor Metastasis Regional lymph node Systemic TCC 11 CIS − − TCC 18a T1 + CIS − − TCC 21 T3b − − TCC 22a T4 + + TCC 25 CIS − − TCC 38 T2 − − TCC 44b CIS − − TCC 84a T1 + CIS − − TCC 91 T3b − − -
a Tumor specimens with NY-ESO-1 expression confirmed by immunohistostaining. Frozen specimens from TCC18 for RT-PCR were not available.
-
b Patient TCC44 has been tumor free since September 1995 after transurethral resection of bladder tumor followed by BCG immunotherapy. Serum for NY-ESO-1 antibody test was obtained in October 1997. Sera from the 8 other patients were obtained at the time of surgical resection of their tumors.
-
Volume 61, Issue 12
